Gaps in glucagon fills among commercially insured patients receiving a glucagon prescription

Joseph R Herges; Jordan D Haag; Kimberly A Kosloski-Tarpenning; Kristin C Mara; Rozalina G McCoy

doi:10.1016/j.diabres.2023.110720

Gaps in glucagon fills among commercially insured patients receiving a glucagon prescription

Diabetes Res Clin Pract. 2023 Jun:200:110720. doi: 10.1016/j.diabres.2023.110720. Epub 2023 May 16.

Authors

Joseph R Herges¹, Jordan D Haag², Kimberly A Kosloski-Tarpenning³, Kristin C Mara⁴, Rozalina G McCoy⁵

Affiliations

¹ Department of Pharmacy, Mayo Clinic, Rochester, MN, United States. Electronic address: Herges.Joseph@mayo.edu.
² Department of Pharmacy, Mayo Clinic, Rochester, MN, United States. Electronic address: Haag.Jordan@mayo.edu.
³ Department of Pharmacy, Mayo Clinic Health System, Southeast Minnesota Region, Owatonna, MN, United States. Electronic address: Tarpenning.Kimberly@mayo.edu.
⁴ Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States. Electronic address: Mara.Kristin@mayo.edu.
⁵ Division of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, MN, United States. Electronic address: McCoy.Rozalina@mayo.edu.

PMID: 37196705
PMCID: PMC10278149 (available on 2024-06-01)
DOI: 10.1016/j.diabres.2023.110720

Abstract

Glucagon is critically underutilized, and we explored whether this is due to inadequate glucagon prescribing or the patient's inability to fill prescriptions. Of 216 commercially insured, high-risk individuals with diabetes who were prescribed glucagon in our healthcare system, 142 (65.4%) had a claim indicating its fill within 30 days.

Keywords: Diabetes; Glucagon; Hypoglycemia.

MeSH terms

Diabetes Mellitus* / drug therapy
Glucagon* / therapeutic use
Humans
Prescriptions
Retrospective Studies
United States

Substances

Glucagon

Grants and funding

K23 DK114497/DK/NIDDK NIH HHS/United States